For example, Myc targeted CDK18 affects the interaction of ATR-RAD9 and ATR-ETAA1, and promotes ATR activation, thus promoting homologous recombination and PARP inhibitor resistance in glioma [19]. Here, MYC is linked to central nervous system cancer.